Carthage Area Hospital honors Nurse Jennifer Putnam with DAISY Award
CAH says her compassion during vulnerable moments showcases the essence of nursing. Putnam's commitment reminds the hospital of the significant impact one nurse can have, and the hospital says they are proud to honor her within the North Star Health Alliance.
Traffic Alert: Intersection of Stone Street & Sherman Street in Watertown
8 injured in Pearl Street Mall attack; Law enforcement ID suspect
Mets take home win in Sunday finale against Iowa
Carthage Area Hospital honors Nurse Jennifer Putnam with DAISY Award
West Genesee takes home second straight Class AA championship
'My favorite person in the whole world was my grandmother. When she was near the end of her battle with cancer, a nurse would sing to her each day—bringing her peace and taking away her fear, even if just for five minutes. I knew then that if someone could do that for another person, I wanted to be a part of it,' Putnam shared, reflecting on what drew her to nursing. She said that moment cemented her calling and her first clinical rotation back at Carthage Hospital only deepened her love for patient care.
Putnam is essential to the Carthage ER team, expertly guiding patients and families through critical moments with warmth and kindness. Her considerate support, unfailing generosity, and dedication to reducing pain and anxiety are prime examples of the exceptional care that The DAISY Award® honors, says CAH.
'Jennifer's compassion goes hand in hand with her clinical excellence. She has an uncanny ability to tune into what her patients need most—whether that's a medical intervention or simply someone to listen. By openly sharing her own stories, she builds bridges of trust and eases her patients' fears in their toughest moments. Her empathetic presence transforms the care experience, reminding everyone on our team of the profound impact kindness and genuine connection can have on healing.' David Ferris, MSHA, RN, FACHE, Chief Nursing Officer, Senior Vice President of Patient Care
The North Star Health Alliance and Carthage Area Hospital congratulated Putnam on this earned accolade. CAH praised her unwavering dedication to patient-centered care.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit
Permit approval enables expanded research capabilities and underscores commitment to accuracy, reliability, and scientific excellence BILLERICA, Mass., August 21, 2025--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the New York State Department of Health (NYSDOH) has granted the Quanterix Accelerator Laboratory a clinical laboratory permit in the Clinical Chemistry category. The permit approval expands advanced biomarker research led by Quanterix, deepening collaborations with clinical, pharmaceutical, and research partners. The Quanterix Accelerator Lab is now fully CLIA-certified in all 50 states, enabling comprehensive clinical testing and biomarker analysis nationwide. "Collaboration is at the core of the Quanterix Accelerator Laboratory," said Masoud Toloue, PhD, Chief Executive Officer of Quanterix. "Every breakthrough therapy and clinical trial begins with strong partnerships. Securing this permit reaffirms our commitment to quality and compliance and enables us to extend our expertise to a broader network of clinical and research partners." The Quanterix Accelerator Laboratory is a cutting-edge facility leveraging ultra-sensitive Simoa® technology to deliver unmatched precision in protein biomarker detection, supporting biopharmaceutical research, clinical testing, and custom assay development. Certified under the Clinical Laboratory Improvement Amendments (CLIA) program, the Lab has developed 100+ custom assays and supported over 264 global clinical trials across neurology, immunology/oncology, and infectious diseases, combining rapid turnaround with dedicated project management to accelerate discovery and therapeutic innovation. The latest achievement in a series of growth milestones for the Lab, the new permit underscores Quanterix's commitment to meeting the highest benchmarks for accuracy, reliability, and safety. As one of the nation's largest healthcare markets, New York's clinical testing standards are among the most comprehensive in the country, requiring labs to meet rigorous Clinical Laboratory Evaluation Program (CLEP) standards. Accelerator's Simoa® NfL Laboratory Developed Test (LDT) gained approval as part of the laboratory permitting. Authorizations for additional clinical tests are planned to further broaden the available test menu. Additionally, operating under the Quanterix Accelerator Laboratory, the Lucent Diagnostics brand now provides advanced serum and plasma biomarker testing to the clinical and research community. This integration combines the Accelerator Lab's rigor and ultra-sensitive Simoa® technology with Lucent Diagnostics' focus on delivering actionable clinical insights, expanding the reach and impact of biomarker-driven discovery and diagnostics. To learn more about the Quanterix Accelerator Laboratory, visit: About QuanterixQuanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With more than 3,600 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company®, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,396 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at View source version on Contacts Media Contact Marissa Klaassenmedia@ Sign in to access your portfolio
Business Wire
5 hours ago
- Business Wire
Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit
BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the New York State Department of Health (NYSDOH) has granted the Quanterix Accelerator Laboratory a clinical laboratory permit in the Clinical Chemistry category. The permit approval expands advanced biomarker research led by Quanterix, deepening collaborations with clinical, pharmaceutical, and research partners. The Quanterix Accelerator Lab is now fully CLIA-certified in all 50 states, enabling comprehensive clinical testing and biomarker analysis nationwide. "Every breakthrough therapy and clinical trial begins with strong partnerships. Securing this permit reaffirms our commitment to quality and compliance and enables us to extend our expertise to a broader network of clinical and research partners.' Share 'Collaboration is at the core of the Quanterix Accelerator Laboratory,' said Masoud Toloue, PhD, Chief Executive Officer of Quanterix. 'Every breakthrough therapy and clinical trial begins with strong partnerships. Securing this permit reaffirms our commitment to quality and compliance and enables us to extend our expertise to a broader network of clinical and research partners.' The Quanterix Accelerator Laboratory is a cutting-edge facility leveraging ultra-sensitive Simoa ® technology to deliver unmatched precision in protein biomarker detection, supporting biopharmaceutical research, clinical testing, and custom assay development. Certified under the Clinical Laboratory Improvement Amendments (CLIA) program, the Lab has developed 100+ custom assays and supported over 264 global clinical trials across neurology, immunology/oncology, and infectious diseases, combining rapid turnaround with dedicated project management to accelerate discovery and therapeutic innovation. The latest achievement in a series of growth milestones for the Lab, the new permit underscores Quanterix's commitment to meeting the highest benchmarks for accuracy, reliability, and safety. As one of the nation's largest healthcare markets, New York's clinical testing standards are among the most comprehensive in the country, requiring labs to meet rigorous Clinical Laboratory Evaluation Program (CLEP) standards. Accelerator's Simoa ® NfL Laboratory Developed Test (LDT) gained approval as part of the laboratory permitting. Authorizations for additional clinical tests are planned to further broaden the available test menu. Additionally, operating under the Quanterix Accelerator Laboratory, the Lucent Diagnostics brand now provides advanced serum and plasma biomarker testing to the clinical and research community. This integration combines the Accelerator Lab's rigor and ultra-sensitive Simoa ® technology with Lucent Diagnostics' focus on delivering actionable clinical insights, expanding the reach and impact of biomarker-driven discovery and diagnostics. To learn more about the Quanterix Accelerator Laboratory, visit: About Quanterix Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa ® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With more than 3,600 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company ®, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,396 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at
Business Wire
11 hours ago
- Business Wire
Polaris Pharmacy Services Named Exclusive U.S. Distributor of AstraZeneca's FluMist® Home Service—The World's First At-Home Nasal Spray Flu Vaccine
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- Polaris Pharmacy Services, a leading provider of long-term care and specialty pharmacy solutions, has been selected as the exclusive U.S. distributor for FluMist® Home, AstraZeneca's at-home flu vaccine service available for the 2025-2026 flu season. Through FluMist Home, individuals can order FluMist online to be delivered directly to their home on a date they choose—no doctor's visit or needle required. The program is the first of its kind to receive FDA approval and has officially launched in the U.S. 'We are proud to partner with AstraZeneca to bring this innovative, direct-to-consumer solution to families across the country,' said David Rombro, RPh, Chief Executive Officer of Polaris Pharmacy Services. 'As the exclusive pharmacy distributor for FluMist Home, Polaris is leading the charge in redefining how preventive care is delivered in the U.S.' Andrew Leone, Executive Director Marketing and Sales, US Vaccines & Immune Therapies AstraZeneca said, 'Our partnership with Polaris Pharmacy Services reflects a shared vision to bring cutting-edge innovation and convenience directly to families and communities across the U.S. Together, we are empowering individuals and their families to help bring flu protection home.' Launched in collaboration with its HUB services partner, Asembia, and ASPN Pharmacies—which provides the technology platform and backend services—Polaris has begun dispensing and shipping vaccines from five state-of-the-art pharmacy locations. To support the specialized temperature-control requirements of the product, Polaris has invested in advanced cold chain capabilities at each location, demonstrating the company's commitment to operational excellence and innovation in pharmaceutical logistics. To learn more about FluMist Home and to confirm your eligibility, visit About Polaris Pharmacy Services Experience the future of pharmacy care with Polaris Pharmacy Services. As leaders in specialty, long-term and post-acute care, corrections, and PACE pharmacy solutions, Polaris is elevating pharmacy standards by combining clinical expertise with advanced technology to improve outcomes, optimize costs, and enhance the patient experience. Founded in 2015, Polaris is independently owned with more than 20 pharmacies nationwide.
